Drug intelligence / Profile preview

TQB3616 + abiraterone acetate + prednisone

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of TQB3616, abiraterone acetate, and prednisone. TQB3616 is a novel CDK4/6 inhibitor that reduces intracellular protein phosphorylation levels and prevents cells from entering the synthesis phase, thereby inhibiting cell proliferation. Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen biosynthesis, while prednisone serves as a glucocorticoid replacement therapy to manage side effects of abiraterone acetate. This combination is being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Targets

CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on TQB3616 + abiraterone acetate + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3616 + abiraterone acetate + prednisone.

Explore the full profile